HF
OBIO icon

HRT Financial’s Orchestra BioMed OBIO Stock Holding History

HRT Financial’s Portfolio OBIO Stock Details OBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-28,217
Closed -$75K – 3431
2025
Q2 		$75K Buy
+28,217
New +$82.4K ﹤0.01% 2254
2023
Q2 		– Sell
-29,036
Closed -$568K – 3011
2023
Q1 		$568K Sell
29,036
-20,822
-42% -$241K 0.01% 1273
2022
Q4 		$498K Hold
49,858
– – 0.01% 1429
2022
Q3 		$493K Hold
49,858
– – 0.01% 1594
2022
Q2 		$496K Sell
49,858
-100
-0.2% -$994 0.01% 1586
2022
Q1 		$495K Buy
49,958
+34,149
+216% +$337K ﹤0.01% 1780
2021
Q4 		$158K Buy
+15,809
New +$156K ﹤0.01% 2620

Other funds holding OBIO

RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return
Pathstone Holdings
Pathstone Holdings Englewood, New Jersey $25.1B AUM 22.95% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

HRT Financial's OBIO Position: Q3 2025 in Review

HRT Financial sold out of Orchestra BioMed (OBIO) in Q3 2025, closing a stake of 28,217 shares — an estimated $75K sold.

HRT Financial first reported a position in OBIO in Q4 2021 and held it in 7 quarters. The position peaked at $568K in Q1 2023. 52 funds tracked by Wall St. Rank hold OBIO as of Q3 2025.

  • HRT Financial reported no remaining Orchestra BioMed position as of Q3 2025 after selling out during the quarter.
  • HRT Financial sold 28,217 Orchestra BioMed shares in Q3 2025, an estimated $75K.
  • HRT Financial first reported a position in Orchestra BioMed in Q4 2021 and held it in 7 quarters.
  • HRT Financial's Orchestra BioMed position peaked at $568K in Q1 2023.
  • 52 funds tracked by Wall St. Rank held Orchestra BioMed as of Q3 2025.

Based on HRT Financial's 13F filing for Q3 2025, filed 14 Nov 2025.